Luxembourg vs United Arab Emirates: Protecting minority investors: Ease of shareholder suits index (0-10)
Luxembourg
40
in 2019
United Arab Emirates
40
in 2019
Luxembourg rank
166th
United Arab Emirates rank
166th
Protecting minority investors: Ease of shareholder suits index (0-10) over time
- Luxembourg
- United Arab Emirates
How they compare
Luxembourg currently reports 40 against 40 in United Arab Emirates, a difference of 0.
Across all 7 years both countries report, United Arab Emirates has been ahead every year.
Luxembourg ranks 166th and United Arab Emirates ranks 166th of 191 countries.
United Arab Emirates has averaged higher in every one of the 1 decades both report.
Frequently asked questions
- Which has higher protecting minority investors: ease of shareholder suits index (0-10), Luxembourg or United Arab Emirates?
- Luxembourg, at 40 against 40 in United Arab Emirates as of 2019.
- What is the difference in protecting minority investors: ease of shareholder suits index (0-10) between Luxembourg and United Arab Emirates?
- 0, with Luxembourg ahead.
- How many years of comparable data are there for Luxembourg and United Arab Emirates?
- 7 years are reported by both, from 2013 to 2019.
- How do Luxembourg and United Arab Emirates rank globally for protecting minority investors: ease of shareholder suits index (0-10)?
- Luxembourg ranks 166th and United Arab Emirates ranks 166th of 191 countries.
- Where does this data come from?
- The World Bank, published as Protecting minority investors: Ease of shareholder suits index (0-10) (DB15-20 methodology) - Score. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The score for ease of shareholder suits index benchmarks economies with respect to the regulatory best practice on the indicator. The score is indicated on a scale from 0 to 100, where 0 represents the worst regulatory performance and 100 the best regulatory performance, and is computed based on the methodology in the DB15-20 studies.